英国临床试验单位实用性试验中基于风险监测的评估
该研究通过在线调查英国临床试验单位(CTU),比较其风险评估与监测方法与已发表指南的差异,并为实用性试验中的基于风险监测提出建议。49家单位受邀,23家回复;多数单位对临床试验用药品(CTIMP)和非CTIMP均开展风险评估,并依据 perceived 风险水平制定监测计划,但较少对修订方法进行反思。
要点
- 多数英国CTU报告使用远程与现场结合的监测方式,并对CTIMP和非CTIMP开展风险评估。
- 几乎所有单位依据感知风险水平制定监测,CTIMP中22家、非CTIMP中19家。
- 仅少数单位始终(4家)或有时(9家)审查监测方法,较少利用反思指导未来监测。
核心结论
- 较高比例的英国CTU按指南推荐对CTIMP和非CTIMP使用基于风险的监测,可能提高试验效率并降低成本,但似乎缺乏对修订方法价值的反思。
- CTU之间开展全国合作以改进反思流程并在试验生命周期中做出改变可能有益。
研究设计与样本
- 通过电子邮件邀请英国临床研究协作组注册的CTU参与在线调查,49家单位受邀,23家回复;受访者还被邀请分享风险评估模板。
主要发现
- 多数CTU报告使用远程与现场结合的监测方式。
- 所有单位报告对CTIMP开展风险评估,21家单位对非CTIMP开展风险评估。
- 多数CTIMP风险评估使用MHRA分类,部分也采用员工判断。
- 几乎所有单位依据感知风险水平制定监测,CTIMP中为22家,非CTIMP中为19家。
- 多数情况下制定了监测计划;CTIMP中21家、非CTIMP中18家在试验期间重新审视风险评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Good Clinical Practice guidelines issued in 2016 encourage risk-based approaches to monitoring clinical trials. This study compared current risk assessment and monitoring approaches in UK Clinical Trials Units (CTUs) with the published guidance and makes recommendations for risk-based monitoring in pragmatic trials. METHODS: An online survey of UK Clinical Research Collaboration registered CTUs was administered via email invitation. Forty-nine units were invited, and 23 responded. Respondents were also invited to share copies of risk assessment templates. RESULTS: Most CTUs reported using remote combined with on-site monitoring. All reported undertaking a risk assessment for Clinical Trials of Investigational Medicinal Products (CTIMPs) and 21 units did so for non-CTIMPs. Most CTIMP risk assessments used MHRA (Medicines and Healthcare products Regulatory Agency) classifications, although some also employed staff judgement. Almost all units based their monitoring on perceived risk level; this number was higher for CTIMPs (n = 22) than for non-CTIMPs (n = 19). In most cases, monitoring plans were produced. More CTUs revisited risk assessments during trials in CTIMPs (n = 21) than in non-CTIMPs (n = 18). Small numbers of units reviewed the monitoring approach always (n = 4) or sometimes (n = 9) and few used the reflection to guide future monitoring. CONCLUSIONS: A high proportion of UK CTUs are using risk-based monitoring in the UK, as recommended by guidelines, for both CTIMPs and non-CTIMPs. This has the potential to make trials more efficient and reduce costs. However, there appears to be a lack of reflection on the value of these revised approaches. There may be a benefit in CTUs collaborating nationally to improve processes for reflection and making changes during the life course of a trial.
引用
- Beever D, Swaby L. An evaluation of risk-based monitoring in pragmatic trials in UK Clinical Trials Units. Trials. 2019. PMID: 31500656. doi:10.1186/s13063-019-3619-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。